Protein kinase C and the sub-sensitivity and sub-reactivity of the diabetic rat prostate gland to noradrenaline

Eur J Pharmacol. 2002 Jan 11;434(3):151-61. doi: 10.1016/s0014-2999(01)01541-2.

Abstract

Concentration-response curves to noradrenaline (1 nM-100 microM) were obtained in prostates from 6-week streptozotocin diabetic, insulin-treated diabetic or control rats. Compared to the curve obtained in controls, those obtained in prostates from diabetic and insulin-treated diabetic rats were shifted rightward. The alpha1-adrenoceptor antagonist, prazosin (100 nM), caused a rightward shift of the curves in prostates from all groups. In contrast, the uptake 1 inhibitor, nisoxetine (300 nM), only produced a leftward shift of the curves in prostates from control and insulin-treated diabetic rats. However, frequency-response curves obtained in prostates from both control and diabetic rats were shifted leftward by nisoxetine (300 nM). The concentration-response curve to the alpha1-adrenoceptor agonist, methoxamine (10 nM-100 microM), obtained in prostates from diabetic rats was shifted rightward compared with controls. Calphostin C (500 nM), a protein kinase C inhibitor, caused a leftward shift of the curve in prostates from diabetic, but not control, rats. The protein kinase C inhibitor, bisindolylmaleimide I (500 nM), beta-adrenoceptor antagonist, propranolol (500 nM) and muscarinic cholinoceptor antagonist, atropine (300 nM), had no effect on the noradrenaline concentration-response curves of prostates from control or diabetic rats. Our results suggest that diabetes reduces the sensitivity and reactivity of the prostate to noradrenaline-induced stimulation, and this reduction may be due to changes in protein kinase C activity.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic alpha-Agonists / pharmacology*
  • Adrenergic alpha-Antagonists / pharmacology
  • Adrenergic beta-Antagonists / pharmacology
  • Animals
  • Atropine / pharmacology
  • Diabetes Mellitus, Experimental / enzymology
  • Diabetes Mellitus, Experimental / metabolism*
  • Diabetes Mellitus, Experimental / pathology
  • Dose-Response Relationship, Drug
  • Electric Stimulation
  • Enzyme Inhibitors / pharmacology
  • Fluoxetine / analogs & derivatives*
  • Fluoxetine / pharmacology
  • Immunohistochemistry
  • Indoles / pharmacology
  • Male
  • Maleimides / pharmacology
  • Methoxamine / pharmacology
  • Muscarinic Antagonists / pharmacology
  • Naphthalenes / pharmacology
  • Norepinephrine / antagonists & inhibitors
  • Norepinephrine / pharmacology*
  • Prazosin / pharmacology
  • Propranolol / pharmacology
  • Prostate / drug effects*
  • Prostate / metabolism
  • Protein Kinase C / antagonists & inhibitors
  • Protein Kinase C / metabolism*
  • Rats
  • Rats, Wistar

Substances

  • Adrenergic alpha-Agonists
  • Adrenergic alpha-Antagonists
  • Adrenergic beta-Antagonists
  • Enzyme Inhibitors
  • Indoles
  • Maleimides
  • Muscarinic Antagonists
  • Naphthalenes
  • Fluoxetine
  • nisoxetine
  • Atropine
  • Propranolol
  • Protein Kinase C
  • Methoxamine
  • calphostin C
  • bisindolylmaleimide I
  • Norepinephrine
  • Prazosin